Treatment of malignant melanoma with dacarbazin (DTIC‐DOME) with special reference to urinary excretion of 5‐S‐cysteinyldopa
Seventeen patients were given DTIC, 200 mg/m2/day in five‐day courses every four to six weeks. In four patients (stage II) treated on an adjuvant basis, tumor recurrence has been verified in three. Four of the palliatively treated patients were also given DTIC by regional intra‐arterial infusion with minimal positive tumor effect and minimal toxicity. 5‐S‐cysteinyldopa excretion in urine was check
